SEARCH

SEARCH BY CITATION

References

  • 1
    Snoep JD, Hovens MM, Eikenboom JC, Vander Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. Arch Intern Med 2007;167:15931599.
  • 2
    Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:12061218.
  • 3
    Craven L. Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Miss Val Med J 1953;75:3844.
  • 4
    Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005;46:986993.
  • 5
    Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The seventh ACCP Conference on Antithrombotic and thrombolytic Therapy. Chest 2004;126:234S264S.
  • 6
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:7186.
  • 7
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. prevention of death myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81106.
  • 8
    Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994;308:159168.
  • 9
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. III Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994;308:235246.
  • 10
    Antithrobombotic Trialists’ Collabrative. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:7186.
  • 11
    Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: The relationship among dose, effectiveness, and side effects. Chest 2001;119:39s63s.
  • 12
    Grotemeyer KH, Scharafiinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin nonresponder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397403.
  • 13
    Buchanan MR, Schwartz L, Bourassa M, et al. Results of the BRAT study—a pilot study investigation the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients under going coronary artery bypass surgery. Can J Cardiol 2000;16:13851390.
  • 14
    Andersen K, Hurlen M, Andersen H, Seljeflot I. Aspirin non responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002;108:3742.
  • 15
    Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:16501655.
  • 16
    Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961965.
  • 17
    Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin? Am Heart J 2004;147:293300.
  • 18
    Pamukcu B, Oflaz H, Oncul A, et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of cardiovascular events. J Thromb Thrombolysis 2006;22:103110.
  • 19
    Stejskal D, Vaclavik J, Lacnak B, Proskova J. Aspirin resistant measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 2006;17:349354.
  • 20
    Chen WH, Cheng X, Lee PY, et al. Aspirin resistant and adverse clinical events in patients with coronary artery disease. Am J Med 2007;120:631635.
  • 21
    Chakroun T, Addad F, Abderazek F, et al. Screening for aspirin resistant in stable coronary artery patients by three different tests. Thromb Res 2007;121:413418.
  • 22
    Riley MR, Kasturb EK, Olin BR, et al. Drug facts and comparison, 62nd ed. Lipincott, 2008;11861187.
  • 23
    Mann CC, Plummer ML. The aspirin wars: Money, medicine and 100 years of Rampant competition. Boston , MA : Harvard Business School Press, 1991;236342.
  • 24
    Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Nurkalem Z, Narin A. High frequency of aspirin resistance in patient with acute coronary syndrome. Tohoku J Exp Med 2005;207:5964.
  • 25
    Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:23312336.
  • 26
    Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 1994;118:801804.
  • 27
    Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230235.
  • 28
    Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003;92:14921494.
  • 29
    Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: Current status and future research. Expert Opin Pharmacother 2005;6:20272045.
  • 30
    Gonzalez-Conejero R, River J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: Heterogeneous response or aspirin failure? Stroke 2005;36:276280.
  • 31
    Tantry US, Etherington A, Bliden KP, Gurbel PA. Antiplatelet therapy, current strategies and future trends. Future Cardiol 2006;2:343366.
  • 32
    Guthikonda S, Lev EI, Kleiman NS. Resistance to antiplatelet therapy. Curr Cardiol Rep 2005;7:242248.
  • 33
    Hanjis C, Frishman WH, Lerner RG. Aspirin resistance mechanisms and clinical implications. Cardiol Rev 2006;14:1825.
  • 34
    Gabriel SA, Betteli CB, Tanighuchi RS, Tristao CK, Gabriel EA, Pereira RP. Aspirin resistance and atherothrombosis. Braz J Cardiovasc Surg 2007;22:96103.
  • 35
    Antonino MJ, Bliden KP, Coppolecchia R, et al. Aspirin responsiveness measured by COX-1 specific and COX-1 non-specific methods in healthy subjects: Clarifying the debate on aspirin ‘resistance’. J Thromb Haemost 2007;5: abstract number PP-WE-797.